When Sanofi announced that its franchise would suffer next year because of U.S. payer contracts, the natural follow-up question was this: Does this mean a diabetes pricing war? If Sanofi had to boost its rebates to win coverage–which the company admits it did–then that means its rivals, including Eli Lilly and Novo Nordisk, have, too.
Targeting different markets naturally requires using different marketing strategies. But for Novartis, which is aiming to become a major respiratory player, its approaches within and outside the U.S. could end up being worlds apart.
Ranbaxy Laboratories in June finally managed to finesse its regulatory problems enough to get a generic of Novartis' Diovan to market, boosting its own fortunes while depriving the Swiss drugmaker of the extra revenues it enjoyed for nearly two years. Next up is a generic of AstraZeneca blockbuster Nexium. The question remains when.
Anyone following the hepatitis C drug market knows that Express Scripts CMO Steve Miller has a strong point of view.
That scary $9 billion damages award a Louisiana jury slapped on Takeda and Eli Lilly earlier this year? A U.S. District judge slashed the bill by more than 99%, saying the new amount is the biggest award allowed under current law.